MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.antiviral.2023.105742

Медицинская библиотека · Antiviral research · 2023

Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?

Zarębska-Michaluk Dorota, Flisiak Robert, Janczewska Ewa, Berak Hanna, Mazur Włodzimierz, Janocha-Litwin Justyna, Krygier Rafał, Dobracka Beata, Jaroszewicz Jerzy, Parfieniuk-Kowerda Anna, Dobrowolska Krystyna, Rzymski Piotr

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND & AIMS: The study aimed to assess the phenomenon of achieving sustained virologic response (SVR) in patients with detectable ribonucleic acid (RNA) of hepatitis C virus (HCV) at the end of treatment (ET) with direct-acting antivirals (DAA), find how this is affected by the type of regimen, and how patients experiencing this differed from non-responders with detectable HCV RNA at the ET.

METHODS

The study included all consecutive patients with detectable HCV RNA at the ET selected from the EpiTer-2 database, a retrospective national multicentre project evaluating antiviral treatment in HCV-infected patients in 2015-2023.

RESULTS

Of the 16106 patients treated with IFN-free regimens with available HCV RNA assessment at the ET and at follow-up 12 weeks after treatment completion (FU), 1253 (7.8%) had detectable HCV RNA at the ET, and 1120 of them (89%) finally achieved SVR. This phenomenon was significantly more frequent in pangenotypic regimens, 10.3% vs. 4.7% in genotype-specific options (p < 0.001), and the highest proportion was documented for glecaprevir/pibrentasvir (13.7%), and velpatasvir/sofosbuvir ± ribavirin (6.9%). Patients ET + FU- treated with these two pangenotypic regimens (n = 668) had less advanced liver disease, were less frequently infected with genotype (GT) 3, and were significantly more likely to be treatment-naïve than 61 non-responders.

CONCLUSIONS

We documented 7.8% rate of patients with detectable HCV RNA at the ET, of whom 89% subsequently achieved SVR, significantly more frequently in the population treated with pangenotypic regimens. Less severe liver disease, more often GT3 infection, and a higher percentage of treatment-naive patients distinguished this group from non-responders.

Для цитирования: Zarębska-Michaluk Dorota, Flisiak Robert, Janczewska Ewa, Berak Hanna, Mazur Włodzimierz, Janocha-Litwin Justyna, Krygier Rafał, Dobracka Beata, Jaroszewicz Jerzy, Parfieniuk-Kowerda Anna, Dobrowolska Krystyna, Rzymski Piotr. Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?. Antiviral research. 2023. DOI: 10.1016/j.antiviral.2023.105742.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.